肿瘤干细胞的自我更新机制

doi:10.3760/cma.j.issn.1673-422X.2014.12.006

摘要/Abstract

摘要： 肿瘤干细胞是一类具有自我更新、分化和高度致瘤能力的细胞亚群，其与肿瘤的发生、发展、复发以及治疗抵抗等密切相关，而其中最重要的特性是自我更新能力。深入研究肿瘤干细胞的自我更新调控机制，对于开发以肿瘤干细胞为靶点的新型靶向治疗药物具有重要意义。

关键词: 肿瘤, 肿瘤干细胞, Polycomb group 蛋白, 信号传导

Abstract: Cancer stem cells comprise a subpopulation with the capacity of selfrenewal, selfdifferentiation and high tumorigenicity. Cancerogenesis, development, relapse and therapeutic resistance are closely related with these cells. The most important characteristics of these cells are the ability to selfrenew. So insight into the regulating mechanism of selfrenewal in cancer stem cells will be important for the development of novel molecular agents targeted the cancer stem cells.

Key words: Neoplasms, Neoplastic stem cells, Polycomb group proteins, Signal transduction

王彤, 祁小飞, 张日. 肿瘤干细胞的自我更新机制[J]. 国际肿瘤学杂志, 2014, 41(12): 896-898.

WANG Tong, QI Xiao-Fei, ZHANG Ri. Self-renewal mechanism of cancer stem cells[J]. Journal of International Oncology, 2014, 41(12): 896-898.

参考文献

［1］ Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells［J］. Cancer Res, 2006, 66(19): 93399344. ［2］ Prezioso C, Orlando V. Polycomb proteins in mammalian cell differentiation and plasticity［J］. FEBS Lett, 2011, 585(13): 20672077. ［3］ Su Y, Deng B, Xi R. Polycomb group genes in stem cell selfrenewal: a doubleedged sword［J］. Epigenetics, 2011, 6(1): 1619. ［4］ Kaustov L, Ouyang H, Amaya M, et al. Recognition and specificity determinants of the human cbx chromodomains［J］. J Biol Chem, 2011, 286(1): 521529. ［5］ Kalushkova A, Frykns M, Lemaire M, et al. Polycomb target genes are silenced in multiple myeloma［J］. PLoS One, 2010, 5(7): e11483. ［6］ Vincent A, Van Seuningen I. On the epigenetic origin of cancer stem cells［J］. Biochim Biophys Acta, 2012, 1826(1): 8388. ［7］ Siddique HR, Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences［J］. Stem Cells, 2012, 30(3): 372378. ［8］ Schuringa JJ, Vellenga E. Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells［J］. Curr Opin Hematol, 2010, 17(4): 294299. ［9］ Rizo A, Olthof S, Han L, et al. Repression of BMI1 in normal and leukemic human CD34+ cells impairs selfrenewal and induces apoptosis［J］. Blood, 2009, 114(8): 14981505. ［10］ Xu Z, Liu H, Lv X, et al. Knockdown of the Bmi1 oncogene inhibits cell proliferation and induces cell apoptosis and is involved in the decrease of Akt phosphorylation in the human breast carcinoma cell line MCF7［J］. Oncol Rep, 2011, 25(2): 409418. ［11］ Kreso A, van Galen P, Pedley NM, et al. Selfrenewal as a therapeutic target in human colorectal cancer［J］. Nat Med, 2014, 20(1): 2936. ［12］ Yu CC, Lo WL, Chen YW, et al. Bmi1 regulates snail expression and promotes metastasis ability in head and neck squamous cancerderived ALDH1 positive cells［J］. J Oncol, 2011. ［13］ Honig A, Weidler C, Husler S, et al. Overexpression of polycomb protein BMI1 in human specimens of breast, ovarian, endometrial and cervical cancer［J］. Anticancer Res, 2010, 30(5): 15591564. ［14］ Luo M, Shen DX, Guo XT, et al. Clinicopathological and prognostic significance of Bmi1 expression in human cervical cancer［J］. Acta Obstet Gynecol Scand, 2011, 90(7): 737745. ［15］ Tu Y, Gao X, Li G, et al. MicroRNA218 inhibits glioma invasion, migration, proliferation, and cancer stemlike cell selfrenewal by targeting the polycomb group gene Bmi1［J］. Cancer Res, 2013, 73(19): 60466055. ［16］ van Vlerken LE, Kiefer CM, Morehouse C, et al. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter［J］. Stem Cells Transl Med, 2013, 2(1): 4352. ［17］ Chatoo W, Abdouh M, Duparc RH, et al. Bmi1 distinguishes immature retinal progenitor/stem cells from the main progenitor cell population and is required for normal retinal development［J］. Stem Cells, 2010, 28(8): 14121423. ［18］ Yadirgi G, Leinster V, Acquati S, et al. Conditional activation of Bmi1 expression regulates selfrenewal, apoptosis, and differentiation of neural stem/progenitor cells in vitro and in vivo［J］. Stem Cells, 2011, 29(4): 700712. ［19］ Pritsker M, Ford NR, Jenq HT, et al. Genomewide gainoffunction genetic screen identifies functionally active genes in mouse embryonic stem cells［J］. Proc Natl Acad Sci, 2006, 103(18): 69466951. ［20］ Lin SL, Chang DC, Ying SY, et al. MicroRNA miR302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways［J］. Cancer Res, 2010, 70(22): 94739482. ［21］ Mathieu J, RuoholaBaker H. Regulation of stem cell populations by microRNAs［J］. Adv Exp Med Biol, 2013, 786: 329351. ［22］ Yu F, Yao H, Zhu P, et al. Let7 regulates self renewal and tumorigenicity of breast cancer cells［J］. Cell, 2007, 131(6): 11091123. ［23］ Guo L, Chen C, Shi M, et al. Stat3coordinated Lin28let7HMGA2 and miR200ZEB1 circuits initiate and maintain oncostatin Mdriven epithelialmesenchymal transition［J］. Oncogene, 2013, 32(45): 52775282. ［24］ Won HY, Lee JY, Shin DH, et al. Loss of Mel18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway［J］. FASEB J, 2012, 26(12): 50025013. ［25］ Harrison H, Farnie G, Howell SJ, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor［J］. Cancer Res, 2010, 70(2): 709718. ［26］ Po A, Ferretti E, Miele E, et al. Hedgehog controls neural stem cells through p53independent regulation of Nanog［J］. EMBO J, 2010, 29(15): 26462658.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.